文献速递临床试验与 GCP基础与转化研究

成人呼吸衰竭及相关适应证的体外生命支持:综述

Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review.
PubMed 文献 · JAMA · 2019-01-01

本综述回顾了成人急性呼吸衰竭体外生命支持(ECLS)的证据演变:早期临床试验未显示获益,2009年后技术改进与证据积累推动其应用。2018年随机试验显示极重度ARDS患者死亡率由46%降至35%,但差异未达统计学显著;贝叶斯事后分析与后续Meta分析提示ECLS可能获益。适应证已扩展至肺移植桥接及肺动脉疾病相关右心衰竭。

要点

  • 2018年随机试验中极重度ARDS患者死亡率ECLS组35% vs 对照组46%,差异未达统计学显著。
  • 贝叶斯事后分析与后续Meta分析提示ECLS对极重度ARDS患者可能有益。
  • ECLS适应证已扩展至肺移植桥接和肺动脉疾病相关右心衰竭的处理。

核心结论

  • ECLS在成人急性呼吸衰竭管理中的作用正被技术进步和不断增加的疗效证据重新定义。
  • 未来该领域的发展将源于技术进步、对体外支持生理学和生物学理解的加深,以及对其可能惠及多种临床疾病治疗的知识增长。

研究设计与样本

  • 综述,回顾成人急性呼吸衰竭体外生命支持的临床试验证据与适应证演变。

主要发现

  • 20世纪70年代和90年代成人急性呼吸衰竭ECLS临床试验未能证明获益,导致该干预使用减少数十年并被局限于少数中心。
  • 2009年两件事交汇提升了ECLS兴趣:急性呼吸衰竭ECLS随机临床试验发表,以及甲型H1N1流感大流行期间重症ARDS患者使用ECLS。
  • 2018年极重度ARDS随机临床试验显示死亡率由46%降至35%,但差异未达统计学显著。
  • 对该试验的贝叶斯事后分析和后续Meta分析共同提示ECLS对极重度ARDS患者有益。
  • 随着支持ECLS使用的证据增加,其适应证扩展至肺移植桥接和肺动脉疾病伴右心衰竭患者的管理。

临床怎么用

  • ECLS现已成为临床实践中可接受的器官支持形式。
  • ECLS适应证包括极重度ARDS、作为肺移植桥接以及肺动脉疾病相关右心衰竭的管理(依据综述所述证据演变)。

局限性

  • 2018年随机临床试验中死亡率从46%降至35%的差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The substantial growth over the last decade in the use of extracorporeal life support for adults with acute respiratory failure reveals an enthusiasm for the technology not always consistent with the evidence. However, recent high-quality data, primarily in patients with acute respiratory distress syndrome, have made extracorporeal life support more widely accepted in clinical practice. OBSERVATIONS: Clinical trials of extracorporeal life support for acute respiratory failure in adults in the 1970s and 1990s failed to demonstrate benefit, reducing use of the intervention for decades and relegating it to a small number of centers. Nonetheless, technological improvements in extracorporeal support made it safer to use. Interest in extracorporeal life support increased with the confluence of 2 events in 2009: (1) the publication of a randomized clinical trial of extracorporeal life support for acute respiratory failure and (2) the use of extracorporeal life support in patients with severe acute respiratory distress syndrome during the influenza A(H1N1) pandemic. In 2018, a randomized clinical trial in patients with very severe acute respiratory distress syndrome demonstrated a seemingly large decrease in mortality from 46% to 35%, but this difference was not statistically significant. However, a Bayesian post hoc analysis of this trial and a subsequent meta-analysis together suggested that extracorporeal life support was beneficial for patients with very severe acute respiratory distress syndrome. As the evidence supporting the use of extracorporeal life support increases, its indications are expanding to being a bridge to lung transplantation and the management of patients with pulmonary vascular disease who have right-sided heart failure. Extracorporeal life support is now an acceptable form of organ support in clinical practice. CONCLUSIONS AND RELEVANCE: The role of extracorporeal life support in the management of adults with acute respiratory failure is being redefined by advances in technology and increasing evidence of its effectiveness. Future developments in the field will result from technological advances, an increased understanding of the physiology and biology of extracorporeal support, and increased knowledge of how it might benefit the treatment of a variety of clinical conditions.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Brodie D, Slutsky AS, Combes A, et al. Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review. JAMA. 2019. PMID: 31408142. doi:10.1001/jama.2019.9302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。